NanoViricides, Inc. (NYSE: NNVC) is developing anti-viral drugs to destroy a wide range of viruses in and on the body as well as in the eye. The company has developed a nanotechnology platform that enables rapid drug development, and has successfully treated 5,000 animals after infection with a wide range of viral diseases including influenza, HIV/AIDS, herpes of the genitals and the eye, adenovirus of the eye, dengue and dengue hemorrhagic fever, rabies and Ebola. Human trials for its influenza cure are planned for the second half of 2014. For more information, visit the company’s website at www.nanoviricides.com